Other
Induction Therapy
0
Pipeline Programs↗
14
Active Trials↗
3
Companies Involved↗
Induction Therapy is an early-stage landscape with 0 programs across 3 companies. The most active players are Bristol-Myers Squibb, Grifols Therapeutics LLC, UCB.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
40
clinical trials
Completed15 · 38%
Recruiting11 · 28%
Unknown status6 · 15%
Terminated3 · 8%
Active, not recruiting2 · 5%
Withdrawn2 · 5%
Other1 · 3%
Clinical Trials
Trial Activity
40 trials
Clinical Study of Induction Therapy Options Based on Molecular Subtyping and MRD in Children and Adolescents With AML
Recruiting·—·Phase 2·NCT06221683·500 enrolled
A Randomized Controlled Study of High-dose Cyclophosphamide Induction Therapy in Adult Patients With HLH
Recruiting·—·N/A·NCT05936086·160 enrolled
NALIRIFOX as Induction Therapy in LAPC
Recruiting·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT06467565·20 enrolled
E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers
Recruiting·—·Phase 1/2·NCT05639972·15 enrolled
OSE2101+FOLFIRI, or FOLFIRI Maintenance After FOLFIRINOX-based Induction Therapy in Advanced or Metastatic PDAC
Active, not recruiting·GERCOR - Multidisciplinary Oncology Cooperative Group·Phase 2·NCT03806309·106 enrolled
Chemotherapy Plus Bevacizumab and Anti-PD-1 Followed by Induction Therapy of Chemotherapy Plus Bevacizumab
Not yet recruiting·—·Phase 2·NCT06415851·36 enrolled
Page 1 of 3
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)